Please assess the completion status of the following clinical trial:

Trial Title: Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologic or cytologic diagnosis of primary or metastatic epithelial cancer or sarcoma located in the head and neck area, lung, abdomen or pelvis.~* Tumors must have an overall dimension greater than 24 cm2 (bidimensional) with one dimensions \>6 cm, by x-ray, CT/MRI scan or clinical exam.~* Age \>18~* Karnofsky \> 70 with life expectancy \>3 months.~* Patients may not begin new hormone therapy within 2 weeks of initiation of protocol treatment.~* No planned initiation of hormone therapy within 2 weeks of protocol therapy~* Adequate bone marrow function: Hb \> 9, white blood cell count (WBC) \> 2,000. Hepatic function \< 3x upper limit of laboratory normal values.~* Laboratory studies will be obtained within 2 weeks prior to randomization.~* Patients with metastatic sites of disease including brain are eligible provided that life expectancy is \> 3 months.~Exclusion Criteria:~* Hematologic-related tumors.~* Tumors overlying critical central nervous system structures including spinal cord, eye or brainstem or require treatment portals over these vital structures.~* Central nervous system tumors~* Evidence of other primary malignancy except for carcinoma in situ of cervix or skin cancer excluding melanoma unless disease free for 2 years prior to randomization~* Patients with spinal cord compression.~* Prior radiation to treatment field.~* Concomitant chemotherapy or chemotherapy within past 2 weeks. Planned initiation of chemotherapy within 2 weeks of completing protocol treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: ACTIVE_COMPARATOR): Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
- Treatment Group-2 (Type: ACTIVE_COMPARATOR): Treatment Group 2-15 treatments with standard radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).